English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Coronavirus disease (COVID-19) is the current global public health concern. To date, no specific, effective, and approved treatment is available. With the rapid increase in the rate of infection, repurposing the use of anti-viral like remdesivir and favipiravir was considered as an option to find promising anti-COVID therapeutics. In this study, we aim to observe hepato-renal safety concerns related to these drugs. This retrospective study was done from May 17 to September 9, 2020, on a total of 1348 hospital records. 182 patients were included in the study, divided into two groups who received remdesivir only (RO) and favipiravir only (FO). The mean age of the respective groups is 59.42 (RO) and 54.64 (FO). The average duration of hospital stay was 11 to 12 days. The mortality rate (28.39%) was higher in the RO group. Mean± SD of both ALT (70.65± 50.25) and AST (62.25± 25.46) levels was increased in the RO group than FO group. On the other hand, Blood urea (56.67± 38.40) and serum creatinine (01.70± 02.41) level was higher in the FO group. Hematuria was absent in both groups, proteinuria was also unremarkable. In patients with Covid-19 receive remdesivir and favipiravir, showed an elevation in the level of hepato-renal markers.

Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 patients: A Cross Sectional Observation in Bangladesh